Second quarter 2026
Filed Aug 6, 2026Scholar Rock reported a $109.9 million net loss and no revenue in the second quarter of 2026 while preparing for a potential apitegromab FDA approval by the September 30, 2026 PDUFA date.
The company advanced apitegromab toward a potential FDA decision and expanded its cash position through ATM proceeds, but remained pre-revenue and reported a $109.9 million quarterly net loss.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | did not record any revenue | – | – |
| Net lossGAAP | $109.9 million | – | – |
| Net loss per common shareGAAP | $0.84 per common share | – | – |
| Research and development expenseGAAP | $58.2 million | – | – |
| General and administrative expenseGAAP | $50.7 million | – | – |
| Stock-based compensationother | $19.7 million | – | – |
| Stock-based compensation in research and development expenseother | $7.5 million | – | – |
| Stock-based compensation in general and administrative expenseother | $12.2 million | – | – |
| Cash, cash equivalents, and marketable securitiesother | $492.1 million | – | – |
| Net cash proceeds from at-the-market programother | $62.8 million | – | – |
What drove it
- The apitegromab BLA review is advancing with the Catalent Indiana fill-finish facility and a second fill-finish facility, representing two independent paths to an FDA approval decision.
- The data package for FDA review of the second fill-finish facility has been submitted, and the company stated that ample supply from that facility is available for commercialization upon FDA approval.
- The company stated that its U.S. Commercial team is prepared to launch apitegromab upon FDA approval.
- Scholar Rock initiated the Phase 2 FORGE trial of apitegromab in patients with FSHD.
- Enrollment and dosing in the Phase 2 OPAL study in infants and toddlers with SMA is ongoing.
- The Phase 1 study of SRK-439 in healthy volunteers is ongoing, with topline data anticipated in late 2026.
Concerns
- Scholar Rock did not record any revenue for the quarters ended June 30, 2026 and 2025.
- The company reported a $109.9 million net loss for the quarter ended June 30, 2026.
- The FDA inspection classification of Catalent Indiana following an April 2026 general site inspection is pending.
- The EMA is awaiting the FDA inspection classification of Catalent Indiana, and the company plans to provide updated guidance on timing for a CHMP opinion upon alignment with the EMA.
- The reported cash balance includes $62.8 million in net cash proceeds from the ATM program during the quarter.
What to watch
- Potential FDA approval of apitegromab by the September 30, 2026 PDUFA date.
- FDA review of the submitted data package for the second fill-finish facility.
- FDA inspection classification of Catalent Indiana.
- Alignment with the EMA on next steps for the apitegromab MAA and updated timing guidance for a CHMP opinion.
- Enrollment and dosing progress in the Phase 2 OPAL study.
- Topline data from the Phase 1 SRK-439 study anticipated in late 2026.
Balance sheet and cash flow
- Cash, cash equivalents, and marketable securities of $492.1 million as of June 30, 2026.
- Net cash proceeds of $62.8 million from the Company’s at-the-market (ATM) program during the quarter ended June 30, 2026.
Analysis
Scholar Rock remained pre-revenue in the second quarter of 2026, reporting no revenue and a GAAP net loss of $109.9 million. The loss was nearly unchanged from the $110.0 million net loss reported for the quarter ended June 30, 2025, while net loss per common share was $0.84 compared with $0.98 per common share. The financial profile remains centered on funding development activities and launch preparation ahead of a potential apitegromab approval.
Operating expenses reflected continued investment in the lead program and commercial readiness. Research and development expense was $58.2 million compared with $62.4 million in the prior-year quarter, while general and administrative expense was $50.7 million compared with $49.7 million. Total stock-based compensation was $19.7 million compared with $24.4 million, with $7.5 million included in research and development expense and $12.2 million included in general and administrative expense.
The principal business development is the advancing BLA review for apitegromab in SMA. Management stated that the review is progressing through both the Catalent Indiana fill-finish facility and a second fill-finish facility. The company submitted the data package for FDA review of the second facility and stated that ample supply from that facility is available for commercialization upon FDA approval. The key remaining manufacturing-related variable disclosed is the pending FDA inspection classification of Catalent Indiana following an April 2026 general site inspection.
Scholar Rock is also preparing commercially and broadening clinical development. The U.S. Commercial team is prepared to launch apitegromab upon FDA approval, while the company initiated the Phase 2 FORGE study in FSHD and continued enrollment and dosing in the Phase 2 OPAL study in younger SMA patients. Separately, the Phase 1 study of SRK-439 is ongoing, with topline data anticipated in late 2026. The FDA action date of September 30, 2026 is the central near-term milestone, while EMA timing remains contingent on engagement with the agency and the Catalent Indiana inspection classification.
Liquidity was $492.1 million in cash, cash equivalents, and marketable securities as of June 30, 2026. This balance reflected $62.8 million in net cash proceeds from the ATM program during the quarter. The financing supports the stated regulatory, commercial, and clinical objectives, but also shows that the company raised equity capital during a period in which it continued to report no revenue and a substantial quarterly loss.
Management, verbatim
We are on the threshold of securing the world’s first ever regulatory approval of a myostatin inhibitor, which will also be the first ever muscle-targeted treatment for children and adults living with SMA.
David L. Hallal, Board Chair and Chief Executive Officer of Scholar Rock
Backed by a strong balance sheet, our Scholar Rock team is ready to usher in the next phase of innovation for the SMA community in the U.S. immediately upon apitegromab approval.
David L. Hallal, Board Chair and Chief Executive Officer of Scholar Rock
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating income or loss
- Operating margin
- Income tax expense or benefit and tax rate
- Non-GAAP revenue, earnings, EPS, or operating metrics
- Operating cash flow
- Free cash flow
- Capital expenditures
- Debt and debt maturities
- Share repurchases
- Dividend information
- Prior-quarter comparisons for reported metrics
- Segment revenue
- Financial guidance for revenue, gross margin, operating expenses, or tax rate
- Prior outlook for comparison with actual results
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.